Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,088,790

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic Launches Grafton DBM Bone Grafting Product in Japan

by Zacks Equity Research

Grafton DBM to strengthen Medtronic's (MDT) foothold in Japan.

Medtronic Gets FDA Approval for Accurian RF Ablation Platform

by Zacks Equity Research

Medtronic's (MDT) RF ablation platform will use radio waves to provide relief from chronic pain.

Integra Rides on Channel Expansion Strategy, New Alliances

by Zacks Equity Research

Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.

ResMed Inks Deal With PharMerica on Medication Management

by Zacks Equity Research

The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.

DexCom (DXCM) Gets Health Canada Approval for G6 CGM System

by Zacks Equity Research

DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.

Masimo (MASI) Q4 Earnings and Revenues Beat, Guidance Solid

by Zacks Equity Research

Masimo (MASI) sees an increase in shipments of noninvasive technology in Q4.

Masimo and Saudi Arabia MOH Collaborate for CCHD Screening

by Zacks Equity Research

Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.

Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?

by Zacks Equity Research

Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.

What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?

by Zacks Equity Research

Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.

HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.

What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?

by Zacks Equity Research

Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.

Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.

Here's What Will Give Shape to Medtronic's (MDT) Q3 Earnings

by Zacks Equity Research

Medtronic (MDT) is expected to maintain a decent market share in the core pacing backed by the continued uptake of Micra Transcatheter Pacing System in Q3.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

What's in the Offing for DaVita (DVA) This Earnings Season?

by Zacks Equity Research

DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.

Can Canadian Market Drive Canopy Growth (CGC) Q3 Earnings?

by Zacks Equity Research

Canopy Growth (CGC) is expected to benefit from solid top-line contribution from the Canadian medical cannabis market and the legalization of the recreational use of cannabis in Q3.

Can Global Industrial Unit Aid Ecolab's (ECL) Q4 Earnings?

by Zacks Equity Research

Ecolab's (ECL) preliminary Q4 earnings are likely to fall short of estimates.

3 Medical Instruments Stocks Likely to Beat Estimates in Q4

by Zacks Equity Research

Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.

Why Masimo (MASI) Could Beat Earnings Estimates Again

by Zacks Equity Research

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Stock Market News For Jan 10, 2019

by Zacks Equity Research

Wall Street rallied for the fourth successive day owing to positive developments on the trade front and Fed Chair???s indication of maintaining caution on further interest rate hikes.

Masimo's (MASI) Preliminary Results for 2018 Cheer Investors

by Zacks Equity Research

Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.

Here's Why Investors Should Hold Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.

Masimo (MASI) Down 3.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

by Zacks Equity Research

DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.